Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of CKD-393 vs Co-administration of CKD-501, D759, and D150 in Healthy Adults
NCT04706286Phase 1Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Feb 2021
- Primary completion
- Mar 2021
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-393 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under Curve last at 48 hours and Peak Plasma Concentration at 48 hours. Status: unknown.
02
Drugs
CKD-393
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04706286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04706286.